Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: Sevelamer carbonate prevents vascular calcification

American Journal of Nephrology

Volumn 29, Issue 6, 2009, Pages 582-591

  Tokumoto, Masanori ^a   Mizobuchi, Masahide ^a   Finch, Jane L ^a   Nakamura, Hironori ^a   Martin, Daniel R ^a   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Mortality rates; Myocardial hypertrophy; Renal failure; Vascular calcification

Indexed keywords

CALCIUM; CREATININE; ENALAPRIL; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HEART VENTRICLE HYPERTROPHY; HYPERPHOSPHATEMIA; KIDNEY FUNCTION; MORTALITY; NEPHRECTOMY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY HYPERPARATHYROIDISM; UREMIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CALCINOSIS; CARDIOMEGALY; CHELATING AGENTS; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; HYPERPARATHYROIDISM, SECONDARY; POLYAMINES; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; UREMIA;

EID: 58149457209     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000192844     Document Type: Article

References (48)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1988;32(5 suppl 3):S112-S119.
2. Longenecker JC, Coresh J, Powe NR, et al: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE study. J Am Soc Nephrol 2002;13:1918-1927.
3. Stack AG, Bloembergen WE: Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 2001;12:1516-1523.
4. Brewster UC, Perazella MA: The renin-an-giotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116: 263-272.
5. Hannedouche T, Landais P, Goldfarb B, et al: Randomized controlled trial of enalapril and beta blockers in nondiabetic chronic renal fa ilure. BMJ 1994;309: 833-837.
6. Hou FF, Zhang X, Zhang GH, et al: Efficacy and safety of benazepril for advanced chronic insufficiency. N Engl J Med 2006;354:131-140.
7. Kamper AL, Strandgaard S, Leyssac PP: Effect of enalapril on the progression of chronic renal failure: a randomized controlled trial. Am J Hypertens 1992;5:423-430.
8. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin- converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334: 939-945.
9. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003;361: 117-1 2 4 .
10. Parga M, Andrade CF, Luno J, et al: Antiproteinuric efficacy of losartan in comparison with amlodipine in nondiabetic proteinuric renal disease: a double-blind, randomized clinical trial. Nephrol Dial Transplant 2003;18: 180 6 -1813.
11. Remuzzi A, Perico N, Sangalli F, et al: ACE inhibition and ANG II receptor blockade improve the glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999;276:F457-F466.
12. Ruilope LM, Aldigier JC, Ponticelli C, et al: Safety of the combination of valsartan and benaz epri l i n pat ients w it h ch ron ic rena l disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89-95.
13. Russo D, Minutolo R, Pisani A, et al: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
14. Zucchelli P, Zuccala A, Borghi M, et al: Longterm comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992;42:452-458.
15. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
16. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al: ACE inhibitors and AT1 antagonists - beyond the hemodynamic effect. Nephrol Dial Transplant 2000;15:561-565.
17. Brasier AR, Recinos AR, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002;22:1257-1266.
18. Dohi Y, Ohashi M, Sugiyama M, et al: Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003;26:691-697.
19. Dahlöf B, Devereux RB, Kjeldsen SE, et al;for the LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
20. Wilson PW, Kauppila LI, O'Donnell CJ, et al: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mor tality. Circulation 2001;103:1529-1534.
21. Keelan PC, Bielak LF, Ashai K, et al: Longterm prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation 2001;104: 412-417.
22. Blacher J, Guerin AP, Pannier B, et al: Arterial calcifications, arterial stiffness and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
23. London GM, Guerin AP, Marchais SJ, et al: Arterial media calcification in end stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003;18:1731-1740.
24. Wang AY, Wang M, Woo J, et al: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14:159-168.
25. Bostrom K, Watson KE, Horn S, et al: Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993;91: 1800-1809.
26. Giachelli CM, Bae N, Almeida M, et al: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993;92:1686 -1696.
27. Fitzpatrick LA, Severson A, Edwards WD, et al: Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest 1994;94: 1597-160 4.
28. Shanahan CM, Cary NR, Metcalfe JC, et al: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 1994;93:2393-2402.
29. Shanahan CM, Cary NR, Salisbury JR, et al: Media localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999;100:2168-2176.
30. Shioi A, Nishizawa Y, Jono S, et al: Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995;15: 2003-2009.
31. Jono S, McKee MD, Murry CE, et al: Phosphate regulation of vascular smooth muscle cel l calcif ication. Circ Res 2000;87:E10-E17.
32. Chen H, O' Neill K, Duan D, et al: Phosphorus and uremic serum upregulate osteopontin expression vascular smooth muscle cells. Kidney Int 2002;62:1724-1731.
33. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary artery and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
34. Block GA, Raggi P, Bellasi A, et al: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis pat ients. Kidney Int 2007;71:438-441.
35. Cozzolino M, Staniforth ME, Liapis H, et al: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in longterm experimental uremia. Kidney Int 2003;64:1653-1661.
36. Mizobuchi M, Finch JL, Martin DR, et al: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709-715.
37. Efrati S, Zaidenstein R, Dishy V, et al: ACE inhibitors and survival of hemodialysis patients. Am J K idney Dis 2002;40:1023-1029.
38. Grieve DJ, Shah AM: Oxidative stress in heart failure: more than just damage. Eur Heart J 2003;24:2161-2163.
39. Kameda K, Matsunaga T, Abe N, et al: Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease: possible role for left ventricular remodeling. Eur Heart J 2003;24: 2180-2185.
40. Yasunari K, Maeda K, Watanabe T, et al: Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004;43: 2116-2123.
41. Cannella G, Paoletti E, Delfino R, et al: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997;30: 659-664.
42. Mizobuchi M, Morrissey J, Finch JL, et al: Combination therapy with an angiotensinconverting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796 -1806.
43. Kalantar-Zadeh K, Ikizler TA, Block G, et al: Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003;42:864-881.
44. Raggi P: Effects of excess calcium load on the cardiovascular system measured with electron-beam tomography in end-stage renal disease. Nephrol Dial Transplant 2002;17: 332-335.
45. Qunibi W, Nolan C, Ayus J: Cardiovascular calcification in patients with end stage renal disease: a century-old phenomenon. Kidney Int 2002;62(suppl 82):S73-S80.
46. Block GA, Klassen PS, Lazarus JM, et al: Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15: 2208-2218.
47. Oh J, Wunsch R, Turzer M, et al: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002;106:100-105.
48. Neves KR, Graciolli FG, dos Reis LM, et al: Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007;71: 1262-1270.